

Precis:

Patients with metastatic melanoma who are HLA-A201 positive and HIV and Hepatitis B negative and who have previously been immunized to the gp100 antigen will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine and then will be treated by the adoptive transfer of cloned lymphocytes reactive with shared antigens on their tumors. This study will evaluate the toxicity, immunologic effects and potential therapeutic role of this treatment.